Spyre Therapeutics, Inc. (SYRE) Misses Q3 EPS by 54c

Spyre Therapeutics, Inc. (NASDAQ: SYRE) reported Q3 EPS of ($1.36), $0.54 worse than the analyst estimate of ($0.82).

For earnings history and earnings-related data on Spyre Therapeutics, Inc. (SYRE) click here.

You May Also Be Interested In

• Yen Jumps More Than 1% To Trade At 158.22 Per Us Dollar
• Ollie's Bargain Outlet (OLLI) Tops Q2 EPS by 28c, Offers Guidance
• DA Davidson Reiterates Buy Rating on Jack Henry (JKHY) Following Cybersecurity Incident